Please find attached the outcome.
MUKKA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 0.3 pts less than its Animal Feed peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mukka Proteins Limited's Board approved FY2026 audited results showing strong standalone revenue growth of 37.7% (₹11,849.5M vs ₹8,603.5M) and consolidated revenue growth of 43.2% (₹14,035.2M vs ₹9,800.3M). PAT grew modestly at 1.7% standalone (₹424.1M) and 12% consolidated (₹520.6M). The Board approved raising ₹75 crore via non-convertible debentures (₹25 crore + ₹50 crore), investing ₹2.55 lakh in a new partnership firm MPL FC HRC JV (51% stake), and investing ₹2.5 crore in a Sri Lankan entity Lanka Bio Proteins Private Limited (49% stake). Auditors issued unmodified (clean) opinions on both standalone and consolidated results. The company reported negative operating cash flows for both standalone (₹-1,610M) and consolidated (₹-1,113M), with current borrowings increasing significantly to fund working capital and expansion.
Revenue growth exceeds 20% threshold, signaling strong top-line performance. However, negative operating cash flows and rising debt levels are concerning for shareholders, indicating the company is relying heavily on borrowings to fund operations and growth. The new investments in Sri Lanka and domestic JV suggest expansion plans that may require additional capital.